Q2 EPS Estimate for Eton Pharmaceuticals Raised by Analyst

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Investment analysts at HC Wainwright lifted their Q2 2025 EPS estimates for shares of Eton Pharmaceuticals in a report released on Monday, January 6th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of $0.08 for the quarter, up from their previous estimate of $0.07. HC Wainwright has a “Buy” rating and a $17.00 price objective on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.17) per share. HC Wainwright also issued estimates for Eton Pharmaceuticals’ FY2025 earnings at $0.38 EPS and FY2026 earnings at $0.84 EPS.

Separately, Craig Hallum upped their price objective on Eton Pharmaceuticals from $15.00 to $18.00 and gave the stock a “buy” rating in a report on Wednesday.

Eton Pharmaceuticals Price Performance

ETON opened at $12.01 on Thursday. The stock has a market capitalization of $312.87 million, a P/E ratio of -54.59 and a beta of 1.38. The company’s 50 day simple moving average is $11.64 and its 200-day simple moving average is $7.35. Eton Pharmaceuticals has a one year low of $3.03 and a one year high of $15.00.

Institutional Investors Weigh In On Eton Pharmaceuticals

Several institutional investors have recently modified their holdings of ETON. Westside Investment Management Inc. lifted its holdings in Eton Pharmaceuticals by 5.7% in the third quarter. Westside Investment Management Inc. now owns 618,675 shares of the company’s stock valued at $3,711,000 after buying an additional 33,275 shares during the period. Geode Capital Management LLC raised its position in shares of Eton Pharmaceuticals by 13.5% during the 3rd quarter. Geode Capital Management LLC now owns 272,696 shares of the company’s stock valued at $1,637,000 after acquiring an additional 32,365 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of Eton Pharmaceuticals in the 3rd quarter valued at $90,000. Parkman Healthcare Partners LLC lifted its stake in shares of Eton Pharmaceuticals by 2.8% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 260,226 shares of the company’s stock valued at $1,561,000 after purchasing an additional 7,029 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Eton Pharmaceuticals in the 3rd quarter worth $54,000. Institutional investors and hedge funds own 27.86% of the company’s stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.